Supernus Pharma (SUPN) Reports Q2 EPS of 8c, Guides to Cash Flow Positive in 2015

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. TENB
7. CMG
8. KLAC
9. BIIB
10. ETSY

Go back to Supernus Pharma (SUPN) Reports Q2 EPS of 8c, Guides to Cash Flow Positive in 2015

Supernus Announces Second Quarter 2014 Results

August 11, 2014 5:04 PM EDT

Second quarter combined net product revenue for Oxtellar XR® and Trokendi XR® was $27.6 million. Total revenue for the first half of 2014 was a record, $38.7 million. Raising guidance for annual revenue to approximately $105 million, and expecting to be profitable for the full year. Trokendi XR revenue for the second quarter, $22.6 million, includes prescriptions filled during the first and second quarters, as well as product in the distribution channel as of June 30. Going forward, revenue for Trokendi XR will be recorded based on shipments to wholesalers. Net income in the second quarter was $3.2 million, compared to... More